Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV; Spanish Myeloma Group (GEM/PETHEMA). García-Sanz R, et al. Among authors: payer ar. Haematologica. 2015 Sep;100(9):1207-13. doi: 10.3324/haematol.2015.128439. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069291 Free PMC article. Clinical Trial.
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.
Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste MA, Sarrá J, Ocio E, Ramírez G, Martínez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea AI, Bladé J, Lahuerta JJ, San Miguel JF. Mateos MV, et al. Haematologica. 2015 Aug;100(8):1096-102. doi: 10.3324/haematol.2015.124818. Epub 2015 Apr 24. Haematologica. 2015. PMID: 25911554 Free PMC article. Clinical Trial.
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, Lluch R, Marrero C, Zudaire M, Gironella M, Hernández-Rivas JÁ, Arnan M, Olivier C, Encinas C, Soler JA, Payer ÁR, Casado A, Fernández P, Vilanova D, Bonanad S. de la Rubia J, et al. Among authors: payer ar. J Geriatr Oncol. 2023 Jan;14(1):101401. doi: 10.1016/j.jgo.2022.10.016. Epub 2022 Nov 18. J Geriatr Oncol. 2023. PMID: 36404260 Free article.
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N. Giménez N, et al. Among authors: payer ar. Haematologica. 2019 Mar;104(3):576-586. doi: 10.3324/haematol.2018.196931. Epub 2018 Sep 27. Haematologica. 2019. PMID: 30262568 Free PMC article.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). García-Gutiérrez V, et al. Among authors: payer ar. Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Ann Hematol. 2019. PMID: 30446802 Clinical Trial.
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Bravo J, Baltasar Tello P, González Garcia E, Ríos Herranz E, Páyer AR, Terol Castera MJ, Champ D, Medina Perez A, Gironella M, Fernández Zarzoso M, Forés R, Delgado J, Garcia-Marco JA; GABRIELL Study Group/Investigators. Bravo J, et al. Among authors: payer ar. Leuk Lymphoma. 2023 May;64(5):913-926. doi: 10.1080/10428194.2023.2216327. Epub 2023 May 31. Leuk Lymphoma. 2023. PMID: 37255002 Clinical Trial.
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L, Navarro A, Royo C, Santacruz R, López C, Payer AR, Colado E, González M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrió A, Costa D, Clot G, Giné E, López-Guillermo A, Campo E, Beà S. Delgado J, et al. Among authors: payer ar. Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997154 Free PMC article. No abstract available.
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.
Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F; en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Pastor-Galán I, et al. Med Clin (Barc). 2020 Aug 28;155(4):152-158. doi: 10.1016/j.medcli.2019.11.007. Epub 2020 Jan 21. Med Clin (Barc). 2020. PMID: 31980217 English, Spanish.
Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Gonzalez ME, Rubio-Castro A, Dominguez-Iglesias F, Solano J, Alonso-Nogues E, Fernandez-Alvarez C, Zanabili Y, Alonso JM, Payer AR, Vicente JM, Medina J, Sancho JM. Fernandez-Alvarez R, et al. Among authors: payer ar. Leuk Lymphoma. 2015;56(11):3096-102. doi: 10.3109/10428194.2015.1038709. Epub 2015 May 12. Leuk Lymphoma. 2015. PMID: 25860241
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.
Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Pérez-Encinas M, Estrada N, Velez P, Fox ML, García-Gutiérrez V, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Gómez M, Cervantes F. Hernández-Boluda JC, et al. Leukemia. 2018 Feb;32(2):553-555. doi: 10.1038/leu.2017.297. Epub 2017 Sep 22. Leukemia. 2018. PMID: 28935991 No abstract available.
34 results